Abstract: Provided are vesicles derived from bacteria of the genus Paracoccus and a use thereof in which the vesicles efficiently inhibit pathogenic biological factor-induced secretion of inflammatory mediators which induce inflammation, and the vesicles can be advantageously used for the purpose of preparing a composition for preventing, alleviating, or treating inflammatory diseases and be used therefor.

Abstract: Provided is a method for alleviating, preventing or treating a neurodevelopmental disease, neurologic disease, or psychiatric disease, comprising administering to a subject in need thereof a composition including, as an active ingredient, vesicle derived from Micrococcus luteus, wherein the disease including Alzheimer's disease, Parkinson's disease, amyotropic lateral sclerosis, Huntington's disease, epilepsy, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, diabetic neuropathy, autism spectrum disorder, attention deficit hyperactivity syndrome, major depressive disorder, bipolar disorder, anxiety disorders, schizophrenia, obsessive compulsive disorder, post-traumatic stress disorder, dissociative disorders, eating disorders, substance use disorder, and personality disorders occurring as a result of neurogenesis dysfunction or neuroinflammation.

Abstract: The present invention relates to vesicles derived from bacteria of the genus Sphingomonas and a use thereof. These vesicles were significantly decreased in clinical samples of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis as compared to normal individuals. Administration of isolated vesicles suppressed secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles. Upon oral administration, the vesicles were distributed in the brain tissue. Vesicles derived from bacteria of the genus Sphingomonas are envisioned for use in methods of diagnosis, as well as compositions and methods for treating, hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis.

Abstract: Provided is a method for ameliorating, preventing or treating neutrophilic pulmonary diseases, by administering a composition comprising Micrococcus luteus-derived vesicles as an active ingredient, the composition being capable of effectively treating a neutrophilic pulmonary disease mediated by a nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3 inflammasome (NLRP3 inflammasome).

Abstract: Provided is Micrococcus luteus-derived extracellular vesicles and a use thereof and, more particularly, to a composition including Micrococcus luteus-derived extracellular vesicles as an active ingredient for alleviation, prevention, or treatment of metabolic diseases, wherein the composition can effectively treat metabolic diseases occurring as a result of a metabolism disorder, including: metabolic cardiovascular diseases such as metabolic syndrome, arteriosclerosis, stroke, and cardiac failure; metabolic liver diseases such as non-alcoholic steatohepatitis and hepatocirrhosis; metabolic renal diseases such as diabetic nephropathy, hypertensive nephropathy, and renal failure; and metabolic musculoskeletal disorders such as gout, sarcopenia, and osteoporosis.

Abstract: The present invention relates to vesicles derived from genus Morganella bacteria and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease as compared to normal persons, and the vesicles suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from genus Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cance

Abstract: Provided is a use for preventing and treating neurological diseases or psychiatric diseases, including vesicles derived from Sphingomonas bacteria. The vesicles derived from Sphingomonas bacteria according to the presently claimed subject matter ameliorate symptoms caused by brain damage, such as memory ability and spatial perception ability, when administered to a brain disease mouse model, and therefore, are expected to be usefully used as a composition for preventing, alleviating or treating neurological diseases or psychiatric diseases.

Abstract: Provided are vesicles derived from bacteria belonging to the genus Proteus and a use thereof. The inventors of the present invention experimentally confirmed that the vesicles was significantly reduced in samples of patients with cancers, allergic-respiratory diseases, cardiovascular diseases, metabolic diseases, or neuropsychiatric diseases, as compared to that of normal people, and the vesicles inhibited the secretion of inflammatory mediators due to pathogenic vesicles and also exhibited anticancer efficacy. Therefore, it is anticipated that the vesicles derived from bacteria belonging to the genus Proteus, according to the present invention, may be usefully used for the development of a method of diagnosing cancer, cardiovascular diseases, metabolic diseases, neuropsychiatric diseases, allergic-respiratory diseases, and inflammatory bowel diseases, and a composition for prevention, treatment, and/or alleviation.

Abstract: Provided is a composition for preventing, treating or alleviating eosinophilic inflammatory diseases and Th2 hypersensitivity immune diseases, comprising Lactococcus lactis-derived vesicles, and it was confirmed that, when Lactococcus lactis-derived vesicles according to the presently claimed subject matter were administered to a Th2 hypersensitivity immune disease mouse model, the vesicles inhibited eosinophilic inflammation and the consequent functional and histopathological changes. It was also confirmed that the vesicles inhibited the secretion of Th2 cytokines such as IL-5 and IL-13 in T cells of the Th2 hypersensitivity immune disease mouse model, which is shown by inducing IL-12 secretion that suppresses a Th2 immune response in dendritic cells, which are antigen-presenting cells.

Abstract: The present invention relates to a method of diagnosing cholangiocarcinoma through bacterial metagenomic analysis, and more particularly to a method of diagnosing cholangiocarcinoma by analyzing an increase or decrease in content of specific bacteria-derived extracellular vesicles through bacterial metagenomic analysis using subject-derived samples. Extracellular vesicles secreted from bacteria present in the environment are absorbed into the body, and can directly affect the occurrence of cancer, and cholangiocarcinoma is difficult to diagnose early before symptoms appear so that effective treatment is difficult.

Abstract: The present invention relates to vesicles derived from bacteria belonging to the genus Cupriavidus and a use thereof, the vesicles derived from bacteria belonging to the genus Cupriavidus may be usefully used for the purpose of developing a method of diagnosing a malignant diseases such as gastric cancer, colon cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, prostate cancer, head and neck cancer, lymphoma, and the like, heart diseases such as cardiomyopathy, atrial fibrillation, variant angina, and the like, chronic obstructive pulmonary disease, stroke, diabetes, kidney failure, dementia, Parkinson's disease, or depression, and a composition for preventing or treating the diseases.

Abstract: Provided are a method for preventing, improving, or treating a neurological disorder, mental disorder, senescence, or symptoms thereof, comprising administering to a subject in need thereof vesicles derived from Lactobacillus paracasei as an active ingredient, and a pharmaceutical or functional food composition comprising the vesicles

Abstract: A method of diagnosing prostatic diseases such as prostate cancer, prostatic hyperplasia, and the like through bacterial metagenomic analysis, and more particularly, to a method of diagnosing prostate cancer or prostatic hyperplasia by analyzing an increase or decrease in content of extracellular vesicles derived from specific bacteria through bacterial metagenomic analysis using a subject-derived sample. An extracellular vesicle secreted from a bacterium present in the environment can be absorbed into the body and directly affect the occurrence of inflammation and cancer, and prostatic diseases such as prostate cancer, prostatic hyperplasia, and the like is difficult to diagnose early on before any symptom appears, which makes efficient treatment difficult.

Abstract: Provided is a method of diagnosing lymphoma by analyzing an increase or decrease in contents of specific bacterial extracellular vesicles by performing bacterial metagenomic analysis using normal individual and subject-derived samples, wherein a lymphoma risk group may be diagnosed and predicted early to delay the time of onset or prevent the onset of lymphoma with proper cure, and after onset, early diagnosis may be performed, thereby reducing the incidence of lymphoma and increasing a therapeutic effect.

Abstract: Provided is a method for preventing, alleviating, or treating a viral infectious disease or a respiratory disease, comprising administering a composition containing vesicles derived from Lactobacillus paracasei as an active ingredient to a subject in need thereof, wherein the vesicles may be orally administered and delivered to the lung to suppress a respiratory disease, administered to a COVID-19 virus- or influenza virus-infected model to suppress the replication of the COVID-19 virusand clinical symptoms caused by the influenza virus.

Abstract: A method of diagnosing breast cancer through bacterial and archaeal metagenomic analysis is provided, and more particularly, a method of diagnosing breast cancer by analyzing an increase or decrease in content of extracellular vesicles derived from specific bacteria and archaea through bacterial and archaeal metagenomic analysis using a sample derived from a subject. Extracellular vesicles secreted from bacteria or archaea present in the environment are absorbed into the human body, and thus may directly affect the occurrence of cancer, and it is difficult to diagnose breast cancer early before symptoms occur, and thus efficient treatment therefor is difficult. A risk of developing breast cancer can be predicted through bacterial and archaeal metagenomic analysis using a human body-derived.

Abstract: Provided are a composition for regulating stem cell function comprising the genus Lactobacillus bacteria-derived extracellular vesicles as an active ingredient, and a method for regulating a stem cell function using the same, wherein the genus Lactobacillus bacterial-derived extracellular vesicles have the effect of greatly improving the proliferation of stem cells, and the extracellular vesicles are naturally secreted from a symbiotic the genus Lactobacillus strain in human tonsillar tissue and are human-friendly and natural substances, and thus can be used in various research fields by promoting the proliferation of aged stem cells with minimal toxicity and side effects.

Abstract: Provided are a method for preventing, improving, or treating a neurological disorder, mental disorder, senescence, or symptoms thereof, comprising administering to a subject in need thereof vesicles derived from Lactobacillus paracasei as an active ingredient, and a pharmaceutical or functional food composition comprising the vesicles.

Abstract: Provided is a method for preventing, alleviating or treating an ocular disease including administering a composition containing vesicles derived from Micrococcus luteus as an active ingredient wherein the vesicles are delivered to the central nervous system including the retina through the blood-brain barrier (BBB); when epithelial cells and macrophages were treated with the vesicles, not only is the secretion of an inflammatory mediator by a biological causative factor considerably inhibited, but also NLRP3 protein expression by a biological causative factor is inhibited; and when the vesicles are administered to a rabbit model with an ocular disease caused by oxidative stress, retinal degeneration is significantly inhibited, thus the vesicles derived from Micrococcus luteus can be used for a composition for preventing, alleviating or treating an age-related ocular disease and an inflammatory ocular disease, including a pharmaceutical or health functional food composition.

Abstract: Provided are vesicles derived from Faecalibacterium prausnitzii and to uses thereof. It has been experimentally confirmed by the present inventors that the vesicles in the clinical samples of patients with gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease were significantly reduced in comparison with a normal person and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited.